NCT05727397View on ClinicalTrials.gov

Efficacy and Safety of RC28-E Versus Aflibercept

PHASE3RecruitingINTERVENTIONAL
Enrollment

432

Participants

Timeline

Start Date

March 14, 2023

Primary Completion Date

November 29, 2025

Study Completion Date

December 29, 2025

Conditions
Wet Age-related Macular Degeneration
Interventions
DRUG

RC28-E

Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 µL dose.

DRUG

Aflibercept

Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 µL dose.

Trial Locations (1)

100730

RECRUITING

Beijing Hospital, Beijing

All Listed Sponsors
lead

RemeGen Co., Ltd.

INDUSTRY